GENETIC SEQUENCING AND IMMUNOHISTOCHEMICAL STAINING IN METASTATIC NON-SMALL CELL LUNG CANCER


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

EML4-ALK gene infusions are detectable in 2-7% of cases of non-small cell lung cancer (NSCLC) and generally identified by fluorescence in situ hybridization. The above tumors are susceptible to crizotinib therapy. Genetic sequencing and immunohistochemical staining revealed crizotinib-sensitive ALK translocation in a patient with metastatic NSCLC.

全文:

受限制的访问

参考

  1. Kwak E., Bang Y., Camidge D. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer // N. Engl. J. Med. - 2010; 363: 1693-703.
  2. Shaw A., Yeap B., Mino-Kenudson M. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK // J. Clin. Oncol. - 2009; 27: 4247-53.
  3. Rikova K., Guo A., Zeng Q. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer // Cell. - 2007; 131: 1190-203.
  4. Soda M., Choi Y., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer // Nature. - 2007; 448: 561-6.
  5. Lipson D., Capelletti M., Yelensky R. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies // Nat. Med. - 2012; 18: 382-6.
  6. Wong D., Leung E., So K. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS // Cancer. - 2009; 115: 1723-33.
  7. Inamura K., Takeuchi K., Togashi Y. et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset // Mod. Pathol. - 2009; 22: 508-15.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2014
##common.cookie##